NCT01508806View on ClinicalTrials.gov

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

Single dose of 0.75 mg, administered as a subcutaneous injection

Trial Locations (1)

2856

Novo Nordisk Investigational Site, Christchurch

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY